FAST NEWS: JW Therapeutics’ loss narrows on lower selling expenses
The latest: Biotech company JW (Cayman) Therapeutics Co. Ltd. (2126.HK) reported on Tuesday its net loss for the first half of 2023 narrowed 11.4% year-on-year to 380 million yuan ($52.1 million). Looking…
RECENT ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
- IPO pitch puts BrainAurora’s earnings under the microscope
-
Linklogis appears to build shaky house on lower fees for suffering customers
9959.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
